EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A. Nast; C. Smith; P. I. Spuls; G. Avila Valle; Z. Bata-Csörgö; H. Boonen; E. de Jong; I. Garcia-Doval; P. Gisondi; D. Kaur-Knudsen; S. Mahil; T. Mälkönen; J. T. Maul; S. Mburu; U. Mrowietz; K. Reich; E. Remenyik; K. M. Rønholt; P. G. Sator; M. Schmitt-Egenolf; M. Sikora; K. Strömer; O. Sundnes; D. Trigos; G. van der Kraaij; N. Yawalkar; C. Dressler

doi:10.1111/jdv.16926

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A. Nast^*
, C. Smith
, P. I. Spuls
, G. Avila Valle
, Z. Bata-Csörgö
, H. Boonen
, E. de Jong
, I. Garcia-Doval
, P. Gisondi
, D. Kaur-Knudsen
, S. Mahil
, T. Mälkönen
, J. T. Maul
, S. Mburu
, U. Mrowietz
, K. Reich
, E. Remenyik
, K. M. Rønholt
, P. G. Sator
, M. Schmitt-Egenolf

M. Sikora, K. Strömer, O. Sundnes, D. Trigos, G. van der Kraaij, N. Yawalkar, C. Dressler

^*Corresponding author for this work

Charité – Universitätsmedizin Berlin
King's College London
Amsterdam UMC - University of Amsterdam
University of Szeged
Office-Based Dermatology Practice, Geel, Belgium
Radboud University Medical Center
Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, España
University of Verona
University of Copenhagen
Guy's and St Thomas' NHS Foundation Trust
University of Helsinki
University Hospital Zürich
International Federation of Psoriasis Associations (IFPA)
Kiel University
University of Hamburg
University of Debrecen
Aarhus University
Municipal Hospital Hietzing, Vienna, Austria
Umeå University
Medical University of Warsaw
Office-Based Dermatology Practice, Mönchengladbach, Germany
University of Oslo
University of Bern

Research output: Contribution to journal › Article › Academic › peer-review

43 Downloads (Pure)

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Original language	English
Pages (from-to)	281-317
Number of pages	37
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	2
DOIs	https://doi.org/10.1111/jdv.16926
Publication status	Published - 1 Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/jdv.16926

Euroguiderm-guideline-on-the-systemic-treatment-of-psoriasis-vulgaris--part-2-specific-clinical-and-comorbid-situation.pdfFinal published version, 1.33 MB

Cite this

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., de Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2021). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 35(2), 281-317. https://doi.org/10.1111/jdv.16926

@article{4909231053624c7eb7b2d4ddad490f0b,

title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations",

abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.",

author = "A. Nast and C. Smith and Spuls, \{P. I.\} and \{Avila Valle\}, G. and Z. Bata-Cs{\"o}rg{\"o} and H. Boonen and \{de Jong\}, E. and I. Garcia-Doval and P. Gisondi and D. Kaur-Knudsen and S. Mahil and T. M{\"a}lk{\"o}nen and Maul, \{J. T.\} and S. Mburu and U. Mrowietz and K. Reich and E. Remenyik and R{\o}nholt, \{K. M.\} and Sator, \{P. G.\} and M. Schmitt-Egenolf and M. Sikora and K. Str{\"o}mer and O. Sundnes and D. Trigos and \{van der Kraaij\}, G. and N. Yawalkar and C. Dressler",

note = "Funding Information: sourcesThe development of this EuroGuiDerm guideline was funded by the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision-making regarding which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline. Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley \& Sons Ltd on behalf of European Academy of Dermatology and Venereology",

year = "2021",

month = feb,

day = "1",

doi = "10.1111/jdv.16926",

language = "English",

volume = "35",

pages = "281--317",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley Blackwell",

number = "2",

}

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, de Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, van der Kraaij, G, Yawalkar, N & Dressler, C 2021, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations', Journal of the European Academy of Dermatology and Venereology, vol. 35, no. 2, pp. 281-317. https://doi.org/10.1111/jdv.16926

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

AU - Nast, A.

AU - Smith, C.

AU - Spuls, P. I.

AU - Avila Valle, G.

AU - Bata-Csörgö, Z.

AU - Boonen, H.

AU - de Jong, E.

AU - Garcia-Doval, I.

AU - Gisondi, P.

AU - Kaur-Knudsen, D.

AU - Mahil, S.

AU - Mälkönen, T.

AU - Maul, J. T.

AU - Mburu, S.

AU - Mrowietz, U.

AU - Reich, K.

AU - Remenyik, E.

AU - Rønholt, K. M.

AU - Sator, P. G.

AU - Schmitt-Egenolf, M.

AU - Sikora, M.

AU - Strömer, K.

AU - Sundnes, O.

AU - Trigos, D.

AU - van der Kraaij, G.

AU - Yawalkar, N.

AU - Dressler, C.

N1 - Funding Information: sourcesThe development of this EuroGuiDerm guideline was funded by the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision-making regarding which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline. Publisher Copyright: © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology

PY - 2021/2/1

Y1 - 2021/2/1

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

UR - https://www.scopus.com/pages/publications/85100540361

U2 - 10.1111/jdv.16926

DO - 10.1111/jdv.16926

M3 - Article

C2 - 33547728

SN - 0926-9959

VL - 35

SP - 281

EP - 317

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 2

ER -

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this